Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the ‘Dutch Gynecological Oncology Audit’

Algera, Marc Daniël; Driel, W.J. van; Slangen, Brigitte; Kruitwagen, Rfpm; Wouters, Michel W.J.M.; Baalbergen, Astrid; Cate, A.D. Ten; Aalders, Anette L.; Kolk, A. Van Der; Kruse, Arnold‐Jan; Jong, A.M.L.D. Van Haaften-de; Swaluw, A.M.G. van de; Visschers, B.A.J.T.; Buis, C.; Gerestein, C.G.; Smeets, C.M.W.H.; Boll, Dorry; Laar, Rafli van de; Ngo, Dat; Davelaar, Elvira M.; Ooms, E.A.; Dorst, E.B.L. van; Schmeink, Channa E.; Es, Euctr; Roes, Eva Maria; Cate, Frances; Rijcken, Fleur E.M.; Dunné, F.M.R. Rosier-van; Fons, Guus; Jansen, Gunther; Verhoeve, Harold R.; Nagel, H.T.C.; Keizer, H.H.; Smedts, H.P.M.; Ebisch, I.M.W.; Lande, Jonas van de; Louwers, J.A.; Briët, Justine M.; Waard, Judith de; Diepstraten, Jeroen; Vollebergh, Jos H.A.; Avoort, Irene A.M. van der; Dijk, J.E.W. Van; Lange, J.G.; Mens, J.W.; Gaarenstroom, K.N.; Overmars, K.; Vries, Leonie C. De; Hofman, Laura; Bartelink, Lidewij R.; Verbruggen, M.B.; Vos, MC; Huisman, Margriet A.; Kleppe, Marjolein; Hende, Muriel van den; Aa, M. van der; Wüst, Miriam; Baas, M.I.; Engelen, M.J.A.; Scheers, E.C.A.H.; Moonen-Delarue, M.W.G.; Tjiong, Ming Y.; Leffers, Ninke; Reesink, N.; Timmers, Petra; Kolk, P.; Vencken, P.M.L.H.; Yigit, Refika; Smit, R.A.; Westenberg, S.M.; Coppus, S.F.P.J.; Stam, T.; Schukken, Tineke; Baal, W.M. van; Plas-Koning, Y.W.C.M. van der; Ham, Maaike A.P.C. van

doi:10.1016/j.ygyno.2022.02.013

Cited by 15 publications

(9 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Keeping in mind that gyne-oncology accounts not only for 35.1% of overall gynecology patients (GYN* 1 ) but also for 52.9% of the department’s revenue generation (GYN* 2 ), the feared medical damage relating to diagnostics and treatment delays, failing screening procedures, and related worsened treatment outcome is accompanied with a possibly fierce recess in the economic performance. While the data expand previous observations by confirming the total patient number of gyne-oncology to decrease for the whole COVID-19 pandemic, it depicts a varying effect on the specific malignant main diagnoses [ 9 , 10 , 14 , 30 ].…”

Section: Discussionsupporting

confidence: 80%

“…The visualization of the relative monthly development of patient numbers leads to the following observations that expand the previous scientific status quo [ 9 , 10 , 12 , 14 , 16 , 30 ]. Obstetric care appears to not have been affected to a large extent by the effects of the COVID-19 pandemic in terms of admitted cases at Marburg University Hospital, this expands the finding to the second year of the pandemic [ 12 ].…”

Section: Discussionmentioning

confidence: 71%

“…Therefore, they have evidenced a significant decrease in colorectal and breast cancer interventions by 35.71% and 10.36% in the Abruzzo region in Italy [ 28 ]. Our study expands on these previous findings by diving deeper into the gynecology and gyne-oncology disease spectrum as current literature limits assessment to singular or few diseases, shorter time periods and, furthermore, it neglects the influence on an economic level, a gap this article aims to fill in [ 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 79%

“…On the contrary, the literature suggests that obstetrics and gynecology care can be maintained during a pandemic situation without jeopardizing care quality [ 12 , 13 ]. Gyne-oncology has moved into focus on being particularly endangered of negative impact on its care situation [ 14 , 15 , 16 ]. As gyne-oncology not only includes breast cancer, the most common type of female malignant neoplasm, but also accounts for 39.2% of overall malignancies and 27.7% of cancer deaths of German women, it is of utmost societal interest to comprehend the development of gyne-oncology care against the backdrop of the COVID-19 pandemic [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…As gyne-oncology not only includes breast cancer, the most common type of female malignant neoplasm, but also accounts for 39.2% of overall malignancies and 27.7% of cancer deaths of German women, it is of utmost societal interest to comprehend the development of gyne-oncology care against the backdrop of the COVID-19 pandemic [ 17 ]. Nevertheless, most articles only assess the progression of singular or few diseases, limit their study design to short time periods of a few months, or neglect subsequent impact on an economic level [ 14 , 15 , 16 ]. This insufficient reporting situation called for a more nuanced scientific assessment of the impact of the COVID-19 pandemic on gyne-oncological treatment that takes the whole treatment spectrum and longer time period into consideration and, furthermore, broadens the horizon of observation to health policymaking and economics.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Impact of the COVID-19 Pandemic on Gyne-Oncological Treatment—A Retrospective Single-Center Analysis of a German University Hospital with 30,525 Patients

et al. 2022

View full text Add to dashboard Cite

The study pursues the objective of drawing a comparison between the data of gyne-oncology, gynecology, and obstetrics patient collectives of a German university hospital regarding the progression of patient number and corresponding treatment data during the five-year period of 2017–2021 to assess the impact of the COVID-19 pandemic on gyne-oncological treatment. Descriptive assessment is based on data extracted from the database of the hospital controlling system QlikView® for patients hospitalized at the Department of Gynecology and Obstetrics of Marburg University Hospital. Gynecology and gyne-oncology experience a maintained decline in patient number (nGynecology: −6% 2019 to 2020, −5% 2019 to 2021; nGyne-Oncology: −6% 2019 to 2020, −2% 2019 to 2021) with varying effects on the specific gyne-oncological main diagnoses. Treatment parameters remain unchanged in relative assessment, but as gyne-oncology constitutes the dominating revenue contributor in gynecology (35.1% of patients, 52.9% of revenue, 2021), the extent of the decrease in total revenue (−18%, 2019 to 2020, −14%, 2019 to 2021) surpasses the decline in patient number. The study displays a negative impact on the gynecology care situation of a German university hospital for the entire pandemic, with an even greater extent on gyne-oncology. This development not only endangers the quality of medical service provision but collaterally pressurizes gynecology service providers.

show abstract